AbbVie’s Aquipta & GSK’s Jesduvroq Move Closer To EU Market

AbbVie’s migraine prophylactic and GSK’s treatment for anemia associated with chronic kidney disease were both recommended for pan-EU marketing approval by the European Medicines Agency this week.

Close-up of European Names on Maps
Two new drugs are set to be approved for use in Europe soon • Source: Shutterstock

The European Medicines Agency has recommended that two new drugs be approved for marketing in the EU – AbbVie’s Aquipta (atogepant monohydrate), for the prophylaxis of migraine, and GSK’s Jesduvroq (daprodustat), for treating adults with anemia associated with chronic kidney disease (CKD).

More from Europe

More from Geography